[Overrepresentation of specific gene segments of expressed immunoglobulin heavy chain variable region among unmutated and mutated patients with chronic lymphocytic leukemia]. 2011

Zhen Yu, and Zeng-Jun Li, and Shu-Hua Yi, and Ke-Shu Zhou, and Mu Hao, and Jun-Yuan Qi, and Chang-Hong Li, and Lu-Gui Qiu
State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC, Tianjin 300020, China.

OBJECTIVE To investigate the overrepresentation of specific gene segments of immunoglobulin heavy chain variable region (IgVH) among unmutated and mutated chronic lymphocytic leukemia (CLL) patients and its prognostic implication. METHODS Multiplex PCR was used to identify the expression of IgVH segment and its mutation status in CLL. RESULTS Analyses were successfully performed in 80 of 85 samples. Marked skewed IgVH families were disclosed. The most commonly used VH was VH3 (40.0%), followed by VH4 (30.0%), VHI (13.8%), VH2 (10.0%) and VH5, VH7 (2.5%). Fifty-six patients (70.0%) had mutated VH, 24 (30.0%) unmutated VH. Nine cases (11.3%) were with 100% germline sequence. Fifteen cases (15/24, 62.5%) in VH4, 29 (29/32, 90.7%) in VH3, and 4 (4/11, 36.3%) in VH1 had mutated VH. The most frequently used IgVH gene was VH4-39 (13.8%), and VH4-34 (8.8%). J4 (36/66, 54.5%) and D3 (25/66, 37.8%) were the most frequently used in J and D genes. The progression-free survival (PFS) was 82 and 17 months (P = 0.000), and the overall survival (OS) was 90 and 41 months (P = 0.009), respectively, for mutated and unmutated cases. Recurrent CDR3 sequences were found in our patients and 2 patients with VH1-69 had CDR3 sequences highly similar to those reported in literature. CONCLUSIONS There is difference in IgVH gene segment usage and mutational status in different area CLL patients. Recurrent CDR3 sequences were found in specific IgVH gene segments, which highlights the importance of immunoglobulin mediated stimulation in the development of CLL.

UI MeSH Term Description Entries
D007135 Immunoglobulin Variable Region That region of the immunoglobulin molecule that varies in its amino acid sequence and composition, and comprises the binding site for a specific antigen. It is located at the N-terminus of the Fab fragment of the immunoglobulin. It includes hypervariable regions (COMPLEMENTARITY DETERMINING REGIONS) and framework regions. Variable Region, Ig,Variable Region, Immunoglobulin,Framework Region, Immunoglobulin,Fv Antibody Fragments,Fv Fragments,Ig Framework Region,Ig Variable Region,Immunoglobulin Framework Region,Immunoglobulin Fv Fragments,Immunoglobulin V,Antibody Fragment, Fv,Antibody Fragments, Fv,Fragment, Fv,Fragment, Fv Antibody,Fragment, Immunoglobulin Fv,Fragments, Fv,Fragments, Fv Antibody,Fragments, Immunoglobulin Fv,Framework Region, Ig,Framework Regions, Ig,Framework Regions, Immunoglobulin,Fv Antibody Fragment,Fv Fragment,Fv Fragment, Immunoglobulin,Fv Fragments, Immunoglobulin,Ig Framework Regions,Ig Variable Regions,Immunoglobulin Framework Regions,Immunoglobulin Fv Fragment,Immunoglobulin Variable Regions,Regions, Immunoglobulin Variable,Variable Regions, Ig,Variable Regions, Immunoglobulin
D007143 Immunoglobulin Heavy Chains The largest of polypeptide chains comprising immunoglobulins. They contain 450 to 600 amino acid residues per chain, and have molecular weights of 51-72 kDa. Immunoglobulins, Heavy-Chain,Heavy-Chain Immunoglobulins,Ig Heavy Chains,Immunoglobulin Heavy Chain,Immunoglobulin Heavy Chain Subgroup VH-I,Immunoglobulin Heavy Chain Subgroup VH-III,Heavy Chain Immunoglobulins,Heavy Chain, Immunoglobulin,Heavy Chains, Ig,Heavy Chains, Immunoglobulin,Immunoglobulin Heavy Chain Subgroup VH I,Immunoglobulin Heavy Chain Subgroup VH III,Immunoglobulins, Heavy Chain
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D004252 DNA Mutational Analysis Biochemical identification of mutational changes in a nucleotide sequence. Mutational Analysis, DNA,Analysis, DNA Mutational,Analyses, DNA Mutational,DNA Mutational Analyses,Mutational Analyses, DNA
D005260 Female Females
D005803 Genes, Immunoglobulin Genes encoding the different subunits of the IMMUNOGLOBULINS, for example the IMMUNOGLOBULIN LIGHT CHAIN GENES and the IMMUNOGLOBULIN HEAVY CHAIN GENES. The heavy and light immunoglobulin genes are present as gene segments in the germline cells. The completed genes are created when the segments are shuffled and assembled (B-LYMPHOCYTE GENE REARRANGEMENT) during B-LYMPHOCYTE maturation. The gene segments of the human light and heavy chain germline genes are symbolized V (variable), J (joining) and C (constant). The heavy chain germline genes have an additional segment D (diversity). Genes, Ig,Immunoglobulin Genes,Gene, Ig,Gene, Immunoglobulin,Ig Gene,Ig Genes,Immunoglobulin Gene
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Zhen Yu, and Zeng-Jun Li, and Shu-Hua Yi, and Ke-Shu Zhou, and Mu Hao, and Jun-Yuan Qi, and Chang-Hong Li, and Lu-Gui Qiu
July 2022, Leukemia & lymphoma,
Zhen Yu, and Zeng-Jun Li, and Shu-Hua Yi, and Ke-Shu Zhou, and Mu Hao, and Jun-Yuan Qi, and Chang-Hong Li, and Lu-Gui Qiu
June 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Zhen Yu, and Zeng-Jun Li, and Shu-Hua Yi, and Ke-Shu Zhou, and Mu Hao, and Jun-Yuan Qi, and Chang-Hong Li, and Lu-Gui Qiu
November 2022, Zhonghua bing li xue za zhi = Chinese journal of pathology,
Zhen Yu, and Zeng-Jun Li, and Shu-Hua Yi, and Ke-Shu Zhou, and Mu Hao, and Jun-Yuan Qi, and Chang-Hong Li, and Lu-Gui Qiu
August 1989, Proceedings of the National Academy of Sciences of the United States of America,
Zhen Yu, and Zeng-Jun Li, and Shu-Hua Yi, and Ke-Shu Zhou, and Mu Hao, and Jun-Yuan Qi, and Chang-Hong Li, and Lu-Gui Qiu
January 2018, PloS one,
Zhen Yu, and Zeng-Jun Li, and Shu-Hua Yi, and Ke-Shu Zhou, and Mu Hao, and Jun-Yuan Qi, and Chang-Hong Li, and Lu-Gui Qiu
January 2007, Leukemia & lymphoma,
Zhen Yu, and Zeng-Jun Li, and Shu-Hua Yi, and Ke-Shu Zhou, and Mu Hao, and Jun-Yuan Qi, and Chang-Hong Li, and Lu-Gui Qiu
August 2004, Cancer genetics and cytogenetics,
Zhen Yu, and Zeng-Jun Li, and Shu-Hua Yi, and Ke-Shu Zhou, and Mu Hao, and Jun-Yuan Qi, and Chang-Hong Li, and Lu-Gui Qiu
November 2019, Annals of laboratory medicine,
Zhen Yu, and Zeng-Jun Li, and Shu-Hua Yi, and Ke-Shu Zhou, and Mu Hao, and Jun-Yuan Qi, and Chang-Hong Li, and Lu-Gui Qiu
October 2016, Leukemia & lymphoma,
Zhen Yu, and Zeng-Jun Li, and Shu-Hua Yi, and Ke-Shu Zhou, and Mu Hao, and Jun-Yuan Qi, and Chang-Hong Li, and Lu-Gui Qiu
January 1994, Israel journal of medical sciences,
Copied contents to your clipboard!